| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | — | — |
| Sell | — | — | — | — | — | — | — | — | — | — | — | — |
| total | individual payouts | |
|---|---|---|
| 2026 | 0.11 |
—
—
—
—
—
—
—
—
|
| 2025 | 0.12 |
—
—
—
—
—
—
|
| 2024 | 0.09 |
—
—
—
—
—
|
| 2023 | 0.28 |
—
—
—
—
—
—
—
—
—
—
—
—
—
|
| 2022 | 0.44 |
—
—
—
—
—
—
—
—
—
—
—
—
|
| 2021 | 0.16 |
—
—
—
—
—
—
|
| 2020 | 0.13 |
—
—
—
—
—
—
|
| 2019 | 0.31 |
—
—
—
—
—
—
—
—
—
—
—
—
|
| 2018 | 0.42 |
—
—
—
—
—
—
—
—
—
—
—
|
| 2017 | 0.22 |
—
—
—
—
—
—
—
—
—
—
—
—
|
| 2016 | 0.24 |
—
—
—
—
—
—
—
—
—
—
—
—
|
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 1.39 | 2.19 | 2.73 | 3.35 |
| Receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Other | — | — | — | — |
| 1.39 | 2.19 | 2.73 | 3.35 |
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Payables | — | — | — | — |
| ST’ Debt | — | — | — | — |
| Other | — | — | — | — |
| — | — | — | — |
| 10y | 5y | 3y | |
| Sales | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Cash Flow | — | — | — |
| Earnings | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Book Value | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 11.05 | 14.79 | — | — |
—
|
| ’25 | 10.57 | 11.22 | 11.57 | 13.71 |
47.08
|
| ’24 | 11.39 | 18.45 | 17.53 | 14.27 |
61.63
|
| ’23 | 14.20 | 11.33 | 13.99 | 5.69 |
45.21
|
| ’22 | 13.09 | 14.18 | 17.12 | 17.76 |
62.15
|
| ’21 | 6.36 | 8.39 | 9.42 | 19.30 |
43.47
|
| ’20 | 9.93 | 11.18 | 2.27 | 0.00 |
23.37
|
| Year |
|---|
| Year |
|---|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 0.04 | 0.03 | — | — |
—
|
| ’25 | 0.00 | 0.01 | 0.02 | 0.08 |
0.11
|
| ’24 | 0.00 | 0.00 | 0.05 | 0.04 |
0.09
|
| ’23 | 0.13 | 0.06 | 0.08 | 0.16 |
0.43
|
| ’22 | 0.09 | 0.08 | 0.09 | 0.15 |
0.41
|
| ’21 | — | — | 0.01 | — |
0.09
|
| ’20 | 0.06 | 0.09 | 0.00 | 0.00 |
0.15
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ‡‡‡‡ | ‡‡‡‡ | ‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 2.08 | 1.43 | 1.03 | 1.30 | — | — | — |
Low Price
|
| ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 5.79 | 3.35 | 1.96 | 2.04 | — | — | — |
High Price
|
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Employees
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue/Emp
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 62.15 | 45.21 | 61.63 | 47.08 | — | — | — |
Revenue
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 57.10% | 44.48% | 49.80% | 52.45% | — | — | — |
Gross Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 18.52 | 10.60 | 5.17 | 4.72 | — | — | — |
EBT
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 29.80% | 23.45% | 8.38% | 10.02% | — | — | — |
EBT Margin
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Net Income
|
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Depreciation
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.88 | 1.37 | 1.87 | 1.43 | — | — | — |
Revenue/Sh
|
| ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.41 | 0.43 | 0.09 | 0.11 | — | — | — |
Earnings/Sh
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Cash Flow/Sh
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Capex/Sh
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Free CF/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.84 | 1.56 | 1.33 | 1.18 | — | — | — |
Book Value/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 33.00 | 33.00 | 33.00 | 33.00 | — | — | — |
Shares
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 7.41 | 3.53 | 15.11 | 16.36 | — | — | — |
PE Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.61 | 1.11 | 0.73 | 1.26 | — | — | — |
PS Ratio
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.66 | 0.88 | 0.79 | 1.04 | — | — | — |
PB Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.60 | 1.08 | 0.69 | 1.20 | — | — | — |
EV/Sales
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
EV/FCF
|
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Op' Cash Flow
|
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Capex
|
| — | — | — | — | — | — | — | — | — | — | — | — | — |
FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.92 | 1.39 | 2.19 | 2.73 | — | — | — |
Working Cap'
|
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Total Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.92) | (1.39) | (2.19) | (2.73) | — | — | — |
Net Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 60.56 | 51.63 | 43.94 | 38.97 | — | — | — |
Sh' Equity
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 21.44% | 25.16% | 5.90% | 8.47% | — | — | — |
ROA
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 20.16% | 13.39% | 8.37% | 8.49% | — | — | — |
ROIC
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 21.44% | 0.00% | 0.00% | 0.00% | — | — | — |
ROE
|
Permianville Royalty Trust (PVL) delivers pure-play exposure to the Permian Basin’s oil and gas riches through a no-frills royalty structure, passing most cash directly to unitholders without drilling, debt, or operational hassles. Revenue has mirrored oil’s wild ride—from $39.9 million in 2016 to a 2020 COVID low of $23.4 million, exploding to $62.1 million in 2022 amid $90+ crude, and rebounding to $61.6 million in 2024—driving per-share cash flow peaks of $1.88. Gross margins have climbed to 50%, cushioning volatility, while a fortress balance sheet (net cash position, zero leverage) proved resilient in downturns, even as reserves deplete equity from $107 million to $44 million.
Yet valuation screams bargain at 0.73x P/S and 0.79x P/B, trading below asset value amid skepticism on longevity, with stock prices up 270% from 2020 troughs but decoupling from recent revenue gains. Analysts eye 15% upside if oil stabilizes at $70-80, promising double-digit yields for volatility-tolerant yield hunters—but book value’s 59% erosion signals terminal decline risks post-2030 without reinvestment. PVL shines for patient energy bulls, but depletion demands caution.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.